Overview


According to FutureWise analysis the market for Acromegaly in 2023 is US$ 1.63 billion, and is expected to reach US$ 3.07 billion by 2031 at a CAGR of 8.20%.

Acromegaly is a hormonal disorder caused by the pituitary gland producing excessive growth hormone. If left untreated, it can result in abnormal growth of bones, tissues, and organs, leading to various health problems. Acromegaly shows slow progression and is a rare disorder, so it takes considerable time for the state to be identified. If left untreated, the elevated growth hormone can have severe and sometimes life-threatening effects on bodily functions and bone structure. On the contrary, if treated timely, it can significantly mitigate the risk of complications and subside the symptoms, including enlargement of facial features. Additionally, individuals may experience facial changes such as a protruding lower jaw, brow bone, enlarged nose, thicker lips, and wider spacing between teeth. Seeking medical attention promptly if signs and symptoms of acromegaly are present is crucial. While the disorder progresses slowly, early diagnosis is essential for initiating appropriate care and preventing potential severe health issues associated with untreated acromegaly.

In adults, the leading cause of heightened growth hormone production is typically a noncancerous tumor in the pituitary gland. This tumor, known as an adenoma, produces excessive amounts of growth hormone, giving rise to many of the characteristic features of acromegaly. Some symptoms, such as headaches and vision impairments, result from the tumor exerting pressure on adjacent brain tissues. If left untreated, acromegaly can lead to significant health problems, including high BP, joint issues, heart complications, diabetes, and an increased risk of certain types of tumors. However, early intervention and appropriate treatment can prevent or alleviate these complications, underscoring the importance of timely diagnosis and management.

FutureWise Market Research has published a report that provides an insightful analysis of Acromegaly Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Acromegaly Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Ipsen SA
  • Ionis Pharmaceuticals Inc.
  • Glide Pharmaceutical Technologies Ltd
  • Foresee Pharmaceuticals LLC
  • Amryt Pharma plc
  • Strongbridge Biopharma plc
  • Silence Therapeutics plc
  • Peptron Inc
  • Daewoong Pharmaceutical Co Ltd
  • Crinetics Pharmaceuticals Inc.
  • Chiasma Inc.
  • Aegis Therapeutics LLC
  • Novartis AG

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in the Acromegaly Market:

  • In November 2021, ADVANZ PHARMA, a specialty pharmaceutical company specializing in European complex medicines, introduced MYRELEZ (lanreotide) in Norway. This marked the debut of the first generic version of lanreotide for addressing acromegaly, grade 1, and a specific subset of grade 2 gastroenteropancreatic neuroendocrine tumors, along with the associated symptoms related to neuroendocrine tumors.

On the driver side, the increasing prevalence of acromegaly fosters market growth. Raising awareness about acromegaly among individuals and healthcare professionals, so integrating improved diagnostic techniques, early detection, and treatment initiation can expand the market growth. Ongoing research and development and funds raised by the public and private bodies to aid them in this continuous R&D to develop more advanced and novel, effective treatment modalities for acromegaly fuel the market. The increase in healthcare expenditure, expansion of the healthcare industries, and stable healthcare infrastructure aiding in treating acromegaly, such as improvised diagnosis and enhanced access to medicines and treatment in the developing regions, bolsters the market.
However, acromegaly is a rare condition, and it has a relatively small patient population, which can hamper the market growth, especially in marketing specialized treatments. The higher treatment costs, including medications, surgeries, and ongoing care, can also hinder market growth. Due to the lack of curative treatments, it may pose a challenge to the target market growth.

By Types

  • Ectopic Acromegaly
  • Acromegaly Due To Growth Hormone
  • Others

By Diagnosis

  • Medical Imaging
    • Radiography
    • Magnetic Resonance Imaging (MRI)
    • Nuclear Medicine
    • Ultrasound
    • Others
  • Medical Laboratory Investigations
  • Others

By Treatment

  • Medications
    • Somatostatin Analogues
    • Dopamine Agonists
    • Growth Hormone Receptor Antagonists
    • Others
  • Surgery
    • Endonasal Transphenoidal Surgery
    • Transphenoidal Surgery
  • Radiation Diagnosis
  • Others

By End User

  • Hospitals
  • Clinics
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America has registered the largest revenue share in 2022, this is due to its well-established healthcare infrastructure, adequate healthcare resources, growing healthcare spending, and the rising prevalence of acromegaly. In addition, the presence of top pharmaceutical and biotech companies is developing new products and interventions that are contributing to the growth of the market. Moreover, the government is introducing favorable initiatives to curb increasing healthcare expenditure and raising funds for research and development for this disorder so that new advancements in the treatment and drugs can be administered.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Acromegaly Market By Types, By Diagnosis, By Treatment, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Acromegaly Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Acromegaly Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Acromegaly Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Acromegaly Market, By Types Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Ectopic Acromegaly
        2. Acromegaly Due To Growth Hormone
        3. Others

  • 8.   Global Acromegaly Market, By Diagnosis Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Medical Imaging
         1.1. Radiography
         1.2. Magnetic Resonance Imaging (MRI)
         1.3. Nuclear Medicine
         1.4. Ultrasound
         1.5. Others
        2. Medical Laboratory Investigations
        3. Others

  • 9.   Global Acromegaly Market, By Treatment Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Medications
         1.1. Somatostatin Analogues
         1.2. Dopamine Agonists
         1.3. Growth Hormone Receptor Antagonists
         1.4. Others
        2. Surgery
         2.1. Endonasal Transphenoidal Surgery
         2.2. Transphenoidal Surgery
        3. Radiation Diagnosis
        4. Others

  • 10.   Global Acromegaly Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Clinics
        3. Others

  • 11.   North America Acromegaly Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Acromegaly Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Acromegaly Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Acromegaly Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Ipsen SA
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Ionis Pharmaceuticals Inc.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Glide Pharmaceutical Technologies Ltd
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Foresee Pharmaceuticals LLC
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Amryt Pharma plc
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Strongbridge Biopharma plc
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Silence Therapeutics plc
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Peptron Inc
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Daewoong Pharmaceutical Co Ltd
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
         10.Crinetics Pharmaceuticals Inc.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
         11.Chiasma Inc.
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
          12.Aegis Therapeutics LLC
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13.Novartis AG
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 19.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients